Insider · SEC Form 4 filer

RA Capital Nexus Fund II, L.P.

Companies

Where they file as an insider

Janux Therapeutics (JANX) Director Latest filing Jun 11, 2026
Acumen Pharmaceuticals (ABOS) Director Latest filing Jun 3, 2026
Acrivon Therapeutics (ACRV) Director Latest filing May 18, 2026
Werewolf Therapeutics (HOWL) Director, 10% owner Latest filing May 14, 2025
LENZ Therapeutics (LENZ) Director, 10% owner Latest filing Mar 21, 2024

Track record

Did their buys beat the typical stock?

Open-market buys5
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check0

Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.

Werewolf Therapeutics (HOWL) Bought May 12–14, 2025 · $487K · 536,426 shares Behind typical Jun 30, 2025 $1.09 → Dec 31, 2025 $0.63 · −41.9% (typical stock +2.1%)
LENZ Therapeutics (LENZ) Bought Mar 21, 2024 · $15M · 998,009 shares Beat typical Mar 31, 2024 $22.33 → Sep 30, 2024 $23.74 · +6.3% (typical stock +3.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist